The Impact TDCS-linked Motor and Cognitive Training Gains in Parkinson's Disease
NCT04581590, Not applicable, Active not recruiting, Federal University of Paraíba
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | The Impact TDCS-linked Motor and Cognitive Training Gains in Parkinson's Disease | ClinicalTrials.gov |
| NCT number | NCT04581590 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 242 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Federal University of Paraíba | ClinicalTrials.gov |
| Conditions | Parkinson Disease, Cognition Disorder, Motor Disorders | ClinicalTrials.gov |
| Interventions | Cognitive training | ClinicalTrials.gov |
| First posted | 2020-10-09 | ClinicalTrials.gov |
| Last updated | 2025-01-17 | ClinicalTrials.gov |
Registered outcomes 14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Changes dual-task gait speed by the Auditory Stroop Task | [Baseline, after 04 weeks] | For this outcome, the Auditory Stroop Task participants will be asked to walk while listening to words spoken loudly and softly and indicate if the volume heard was loud or low, irrespective of the word pronounced. | ClinicalTrials.gov |
| Secondary | Changes in executive functions assessed by Wisconsin Card Sorting Test (WCST) | [Baseline, after 04 weeks] | The Wisconsin Card Sorting Test (WCST) is a neuropsychological test of "set-shifting", i.e. the ability to display flexibility in the face of changing schedules of reinforcement. A number of stimulus cards are presented to the participant. The participant is told to match the cards, but not how to match; however, they are told whether a particular match is right or wrong. The original WCST used paper cards and was carried out with the experimenter on one side of the desk facing the participant on the other. The test takes approximately 12-20 minutes to carry out and generates a number of psychometric scores, including numbers, percentages, and percentiles of: categories achieved, trials, errors, and perseverative errors. | ClinicalTrials.gov |
| Secondary | Changes in executive functions assessed by Trail Making Test (TMT) | [Baseline, after 04 weeks] | The Trail Making Test (TMT) is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as quickly as possible while still maintaining accuracy.The test can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning | ClinicalTrials.gov |
| Secondary | Changes in executive functions assessed by Verbal Fluency Test | [Baseline, after 04 weeks] | The Verbal Fluency Test are a kind of psychological test in which participants have to produce as many words as possible from a category in a given time (usually 60 seconds). This category can be semantic, including objects such as animals or fruits, or phonemic, including words beginning with a specified letter, such as p, for example | ClinicalTrials.gov |
| Secondary | Changes in executive functions assessed by Montreal Cognitive Assessment (MoCA) | [Baseline, after 04 weeks] | The Montreal Cognitive Assessment (MoCA) is a cognitive screening tool. MoCA is composed of eight cognitive domains, which are scored within a range of 0 to 30 points (higher scores indicate better function): short-term memory; visuospatial skills; executive function; verbal fluency; attention, concentration and working memory; language; sentence repetition; and spatiotemporal orientation. | ClinicalTrials.gov |
| Secondary | Changes in motor functions assessed by Dynamic Gait Index (DGI) | [Baseline, after 04 weeks] | The Dynamic Gait Index (DGI) assess gait, balance and fall risk. It evaluates not only usual steady-state walking, but also walking during more challenging tasks. A four-point ordinal scale, ranging from 0-3. "0" indicates the lowest level of function and "3" the highest level of function (total score = 24). | ClinicalTrials.gov |
| Secondary | Changes in motor functions assessed by 10-meter walk test | [Baseline, after 04 weeks] | The 10-meter walk test to estimate gait speed by recording the average time the patient takes to cover a distance of 10m in three attempts | ClinicalTrials.gov |
| Secondary | Changes in motor functions assessed by Timed Up and Go (TUG) test | [Baseline, after 04 weeks] | The Timed Up and Go (TUG) test to stand up from a chair at the command, walk 3 meters walk along a demarcated course, turn around and walk back to the chair, then sit down. | ClinicalTrials.gov |
| Secondary | Changes in motor functions assessed by Kinematics of Gait | [Baseline, after 04 weeks] | To analyze movement using the Qualisys Motion Capture System (Qualisys Medical AB, 411 13, Gothenburg, Sweden); | ClinicalTrials.gov |
| Secondary | Changes in motor function assessed by the Unified Parkinson's Disease Rating Scale - Part III (UPDRS - III) | [Baseline, after 04 weeks] | For this outcome, the Unified Parkinson's Disease Rating Scale - Part III will be used. Section III provides an overall score for movement-related functions and activities (tremor, stiffness, gait, alternating movements, among others). This section is made up of 33 items, which can range from zero (normal) to four (severe), with responses that are linked to commonly accepted clinical terms. The higher the score, the greater the impairment of motor function. | ClinicalTrials.gov |
| Secondary | Changes in motor function assessed by Activities-specific balance confidence (ABC) scale | [Baseline, after 04 weeks] | For this outcome, Activities-specific balance confidence (ABC) scale to measure the level of confidence in performing daily activities, in addition to identifying fear of falling and possible social isolation | ClinicalTrials.gov |
| Secondary | Changes in sleep quality assessed by Parkinson's disease sleep scale-2 (PDSS-2) | Time Frame: [Baseline, after 04 weeks] | The PDSS is a scale specifically designed to assess sleep quality in individuals with Parkinson's. The PDSS-2 consists of 15 questions rated according to five categories ranging from 0 (never) to 4 (very frequent). Its total score ranges from 0 (no disturbance) to 60 (maximum nighttime disturbance). | ClinicalTrials.gov |
| Secondary | Changes in sleep quality assessed by Pittsburgh Sleep Quality Index (PSQI) | Time Frame: [Baseline, after 04 weeks] | The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire that assesses sleep quality over a one-month time interval. Each component score of the PSQI ranges from 0 to 3, with 3 indicating the greatest dysfunction or disturbance. The seven component scores are then summed to obtain a global PSQI score, which ranges from 0 to 21. Higher scores indicate poorer sleep quality, with a score greater than 5 suggesting significant sleep difficulties. | ClinicalTrials.gov |
| Secondary | Changes in daytime sleepiness assessed by the Epworth Sleepiness Scale (ESS) | Time Frame: [Baseline, after 04 weeks] | The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 34276344 | DERIVED | PubMed |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 6
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Card Sorting Test (Berg) | Secondary outcome | ConductCognition |
| Task Switching Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.3.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 4a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
Release trials-2026-11-12-0.3.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.